| Source: HalifaxProj (inhibit) CGL-Driver Genes |
| Type: Antiapoptotic Oncogene |
| The proteins of BCL-2 family are classified into three subgroups, i.e., the anti-apoptotic/pro-survival proteins represented by BCL-2 and BCL-XL, the pro-apoptotic proteins represented by BAX and Bak, and the pro-apoptotic BH3-only proteins represented by BAD and BID. Since the expression of Bcl-2 protein in tumor cells is much higher than that in normal cells, inhibitors targeting it have little effect on normal cells. |
| 866- | Lae, | Amygdalin from Apricot Kernels Induces Apoptosis and Causes Cell Cycle Arrest in Cancer Cells: An Updated Review |
| - | Review, | NA, | NA |
| 860- | Lae, | Amygdalin as a Promising Anticancer Agent: Molecular Mechanisms and Future Perspectives for the Development of New Nanoformulations for Its Delivery |
| - | Review, | NA, | NA |
| 862- | Lae, | Molecular mechanism of amygdalin action in vitro: review of the latest research |
| - | Review, | NA, | NA |
| 1306- | LE, | Modulations of the Bcl-2/Bax family were involved in the chemopreventive effects of licorice root (Glycyrrhiza uralensis Fisch) in MCF-7 human breast cancer cell |
| - | in-vitro, | BC, | MCF-7 |
| 1317- | LT, | Luteolin Suppresses Teratoma Cell Growth and Induces Cell Apoptosis via Inhibiting Bcl-2 |
| - | vitro+vivo, | Ovarian, | PA1 |
| 2921- | LT, | Luteolin as a potential hepatoprotective drug: Molecular mechanisms and treatment strategies |
| - | Review, | Nor, | NA |
| 2907- | LT, | Protective effect of luteolin against oxidative stress‑mediated cell injury via enhancing antioxidant systems |
| - | in-vitro, | Nor, | NA |
| 2912- | LT, | Luteolin: a flavonoid with a multifaceted anticancer potential |
| - | Review, | Var, | NA |
| 2915- | LT, | Luteolin promotes apoptotic cell death via upregulation of Nrf2 expression by DNA demethylase and the interaction of Nrf2 with p53 in human colon cancer cells |
| - | in-vitro, | Colon, | HT29 | - | in-vitro, | CRC, | SNU-407 | - | in-vitro, | Nor, | FHC |
| 2903- | LT, | Luteolin induces apoptosis by ROS/ER stress and mitochondrial dysfunction in gliomablastoma |
| - | in-vitro, | GBM, | U251 | - | in-vitro, | GBM, | U87MG | - | in-vivo, | NA, | NA |
| 2919- | LT, | Luteolin as a potential therapeutic candidate for lung cancer: Emerging preclinical evidence |
| - | Review, | Var, | NA |
| 2917- | LT, | Rad, | Luteolin acts as a radiosensitizer in non‑small cell lung cancer cells by enhancing apoptotic cell death through activation of a p38/ROS/caspase cascade |
| - | in-vitro, | Lung, | NA |
| 2916- | LT, | Antioxidative and Anticancer Potential of Luteolin: A Comprehensive Approach Against Wide Range of Human Malignancies |
| - | Review, | Var, | NA | - | Review, | AD, | NA | - | Review, | Park, | NA |
| 3531- | Lyco, | Lycopene attenuates the inflammation and apoptosis in aristolochic acid nephropathy by targeting the Nrf2 antioxidant system |
| - | in-vivo, | Nor, | NA |
| 3263- | Lyco, | Lycopene protects against myocardial ischemia-reperfusion injury by inhibiting mitochondrial permeability transition pore opening |
| - | in-vitro, | Nor, | H9c2 | - | in-vitro, | Stroke, | NA |
| 3277- | Lyco, | Recent trends and advances in the epidemiology, synergism, and delivery system of lycopene as an anti-cancer agent |
| - | Review, | Var, | NA |
| 1126- | Lyco, | Lycopene Inhibits Epithelial–Mesenchymal Transition and Promotes Apoptosis in Oral Cancer via PI3K/AKT/m-TOR Signal Pathway |
| - | vitro+vivo, | Oral, | NA |
| 4784- | Lyco, | Protective effects of lycopene in cancer, cardiovascular, and neurodegenerative diseases: An update on epidemiological and mechanistic perspectives |
| - | Review, | Diabetic, | NA | - | Review, | CardioV, | NA |
| 4791- | Lyco, | Investigating into anti-cancer potential of lycopene: Molecular targets |
| - | Review, | Var, | NA |
| 4797- | Lyco, | A mechanistic updated overview on lycopene as potential anticancer agent |
| - | Review, | Var, | NA |
| 4794- | Lyco, | Anticancer Effect of Lycopene in Gastric Carcinogenesis |
| - | Review, | GC, | NA |
| 2533- | M-Blu, | PDT, | Methylene blue-mediated photodynamic therapy enhances apoptosis in lung cancer cells |
| - | in-vitro, | Lung, | A549 |
| 4534- | MAG, | Molecular mechanisms of apoptosis induced by magnolol in colon and liver cancer cells |
| - | in-vitro, | Liver, | HepG2 | - | in-vitro, | CRC, | COLO205 |
| 4518- | MAG, | Cisplatin, | Evaluating the Magnolol Anticancer Potential in MKN-45 Gastric Cancer Cells |
| - | in-vitro, | GC, | MKN45 |
| 4531- | MAG, | Magnolol-induced apoptosis in HCT-116 colon cancer cells is associated with the AMP-activated protein kinase signaling pathway |
| - | in-vitro, | CRC, | HCT116 |
| 4527- | MAG, | Magnolol inhibits growth and induces apoptosis in esophagus cancer KYSE-150 cell lines via the MAP kinase pathway |
| - | in-vitro, | ESCC, | TE1 | - | in-vitro, | ESCC, | Eca109 | - | vitro+vivo, | SCC, | KYSE150 |
| 1314- | MAG, | Magnolol induces apoptosis via activation of both mitochondrial and death receptor pathways in A375-S2 cells |
| - | in-vitro, | Melanoma, | A375 |
| 1782- | MEL, | Melatonin in Cancer Treatment: Current Knowledge and Future Opportunities |
| - | Review, | Var, | NA |
| 1063- | MEL, | HDAC1 inhibition by melatonin leads to suppression of lung adenocarcinoma cells via induction of oxidative stress and activation of apoptotic pathways |
| - | in-vitro, | Lung, | A549 | - | in-vitro, | Lung, | PC9 |
| 496- | MF, | Low-Frequency Magnetic Fields (LF-MFs) Inhibit Proliferation by Triggering Apoptosis and Altering Cell Cycle Distribution in Breast Cancer Cells |
| - | in-vitro, | BC, | MCF-7 | - | in-vitro, | BC, | ZR-75-1 | - | in-vitro, | BC, | T47D | - | in-vitro, | BC, | MDA-MB-231 |
| 520- | MF, | Exposure to a 50-Hz magnetic field induced mitochondrial permeability transition through the ROS/GSK-3β signaling pathway |
| - | in-vitro, | Nor, | NA |
| 4112- | MF, | Novel protective effects of pulsed electromagnetic field ischemia/reperfusion injury rats |
| - | in-vivo, | Stroke, | NA |
| 2259- | MFrot, | MF, | Method and apparatus for oncomagnetic treatment |
| - | in-vitro, | GBM, | NA |
| 1890- | MGO, | The Dual-Role of Methylglyoxal in Tumor Progression – Novel Therapeutic Approaches |
| - | Review, | Var, | NA |
| 930- | MushShi, | Active Hexose Correlated Compound (AHCC) Inhibits the Proliferation of Ovarian Cancer Cells by Suppressing Signal Transducer and Activator of Transcription 3 (STAT3) Activation |
| - | in-vitro, | Ovarian, | NA |
| 1807- | NarG, | A Systematic Review of the Preventive and Therapeutic Effects of Naringin Against Human Malignancies |
| - | Review, | NA, | NA |
| 4976- | Nimb, | Nimbolide inhibits pancreatic cancer growth and metastasis through ROS-mediated apoptosis and inhibition of epithelial-to-mesenchymal transition |
| - | vitro+vivo, | PC, | NA |
| 4977- | Nimb, | Nimbolide Inhibits SOD2 to Control Pancreatic Ductal Adenocarcinoma Growth and Metastasis |
| - | vitro+vivo, | PC, | AsPC-1 | - | in-vitro, | PC, | PANC1 |
| 946- | Nimb, | Nimbolide retards T cell lymphoma progression by altering apoptosis, glucose metabolism, pH regulation, and ROS homeostasis |
| - | in-vivo, | NA, | NA |
| 4630- | OLE, | Targeting resistant breast cancer stem cells in a three-dimensional culture model with oleuropein encapsulated in methacrylated alginate microparticles |
| - | in-vitro, | BC, | NA |
| 4643- | OLE, | HT, | Use of Oleuropein and Hydroxytyrosol for Cancer Prevention and Treatment: Considerations about How Bioavailability and Metabolism Impact Their Adoption in Clinical Routine |
| - | Review, | Var, | NA |
| 4626- | OLE, | A Comprehensive Review on the Anti-Cancer Effects of Oleuropein |
| - | Review, | Var, | NA |
| 4647- | OLEC, | Oleocanthal, an Antioxidant Phenolic Compound in Extra Virgin Olive Oil (EVOO): A Comprehensive Systematic Review of Its Potential in Inflammation and Cancer |
| - | Review, | Var, | NA |
| 1227- | OLST, | Anti-Obesity Drug Orlistat Alleviates Western-Diet-Driven Colitis-Associated Colon Cancer via Inhibition of STAT3 and NF-κB-Mediated Signaling |
| - | in-vivo, | CRC, | NA |
| 2048- | PB, | Sodium Phenylbutyrate Inhibits Tumor Growth and the Epithelial-Mesenchymal Transition of Oral Squamous Cell Carcinoma In Vitro and In Vivo |
| - | in-vitro, | OS, | CAL27 | - | in-vitro, | Oral, | HSC3 | - | in-vitro, | OS, | SCC4 | - | in-vivo, | NA, | NA |
| 2028- | PB, | Potential of Phenylbutyrate as Adjuvant Chemotherapy: An Overview of Cellular and Molecular Anticancer Mechanisms |
| - | Review, | Var, | NA |
| 2045- | PB, | Phenylbutyrate—a pan-HDAC inhibitor—suppresses proliferation of glioblastoma LN-229 cell line |
| - | in-vitro, | GBM, | LN229 | - | in-vitro, | GBM, | LN-18 |
| 1676- | PBG, | Use of Stingless Bee Propolis and Geopropolis against Cancer—A Literature Review of Preclinical Studies |
| - | Review, | Var, | NA |
| 1678- | PBG, | 5-FU, | sericin, | In vitro and in vivo anti-colorectal cancer effect of the newly synthesized sericin/propolis/fluorouracil nanoplatform through modulation of PI3K/AKT/mTOR pathway |
| - | in-vitro, | CRC, | Caco-2 | - | in-vivo, | NA, | NA |
| 1682- | PBG, | Honey, Propolis, and Royal Jelly: A Comprehensive Review of Their Biological Actions and Health Benefits |
| - | Review, | Var, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:27 State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid